News impact
LLY· last 90 days
Eli Lilly and Company
Backward-looking only. These statistics describe how the price moved after past news — nothing more. Sample sizes are small, market context differs every day, and past performance is not indicative of future results. See methodology and disclaimer.
Bullish news (sentiment ≥ 0.3)
9articles
- Avg +24h
- +2.96%
- Avg +72h
- +1.68%
- Avg +7d
- +4.90%
Neutral news (−0.3 to 0.3)
3articles
- Avg +24h
- -0.52%
- Avg +72h
- -1.42%
- Avg +7d
- +7.09%
Bearish news (sentiment ≤ −0.3)
6articles
- Avg +24h
- -2.98%
- Avg +72h
- -2.54%
- Avg +7d
- +7.99%
Per-event price reaction · 18 events
- SeekingAlpha6/16/2026, 2:14:58 PMLilly acquires pain therapy developer 4E TherapeuticsSentiment0.60Relevance100%+24h-2.13%+72h-1.82%+7d-0.47%
- CNBC5/27/2026, 2:57:06 PMHealthy Returns: Eli Lilly makes a new push into vaccines – here’s what to knowSentiment0.60Relevance100%+24h+2.04%+72h-0.07%+7d+3.91%
- CNBC5/26/2026, 11:50:20 AMEli Lilly stock edges higher as company plans nearly $4 billion in vaccine dealsSentiment0.50Relevance100%+24h+5.83%+72h+1.64%+7d+1.32%
- SeekingAlpha5/26/2026, 10:58:28 AMLilly to acquire three vaccine developers in deals worth up to $4BSentiment0.70Relevance100%+24h+5.83%+72h+1.64%+7d+1.32%
- GlobalNewswire5/26/2026, 10:45:00 AMCurevo to be Acquired by Lilly to Advance Next-Generation Shingles PreventionSentiment0.60Relevance85%+24h+5.83%+72h+1.64%+7d+1.32%
- SeekingAlpha5/20/2026, 2:38:29 PMLilly bets up to $202M in non-viral genetic medicines in Engage Bio buyoutSentiment0.50Relevance90%+24h+4.53%+72h+4.50%+7d+10.59%
- BusinessWire5/20/2026, 1:30:00 PMEngage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic MedicinesSentiment0.40Relevance85%+24h+4.53%+72h+4.50%+7d+10.59%
- CNBC5/19/2026, 6:38:37 PMNew data boosts our confidence in Lilly's obesity pill. Plus, Google's new AI featuresSentiment0.30Relevance60%+24h+1.98%+72h+4.24%+7d+6.02%
- CNBC5/4/2026, 6:29:36 PMWhat's behind Eli Lilly's down-and-up day after last week's post-earnings surgeSentiment0.00Relevance60%+24h+1.98%+72h-2.01%+7d+2.27%
- Yahoo4/24/2026, 3:05:29 PMHow Expanding GLP‑1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment StorySentiment0.55Relevance70%+24h-1.77%+72h-1.13%+7d+9.50%
- Yahoo4/24/2026, 2:18:00 PMSpherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity TreatmentSentiment0.10Relevance60%+24h-1.77%+72h-1.13%+7d+9.50%
- Yahoo4/24/2026, 2:10:06 PMBattle Of The Weight-Loss Pills Continues With A Shocking TwistSentiment-0.60Relevance100%+24h-1.77%+72h-1.13%+7d+9.50%
- Yahoo4/24/2026, 2:03:01 PMEli Lilly Shares Dip Despite Stable Growth in GLP-1 PrescriptionsSentiment-0.30Relevance100%+24h-1.77%+72h-1.13%+7d+9.50%
- Yahoo4/24/2026, 1:37:23 PMLilly’s New Obesity Pill Off to Slow Start in Race With NovoSentiment-0.45Relevance100%+24h-1.77%+72h-1.13%+7d+9.50%
- CNBC4/24/2026, 12:08:28 PMStocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and moreSentiment0.00Relevance70%+24h-1.77%+72h-1.13%+7d+9.50%
- Yahoo4/24/2026, 10:46:00 AMLilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelicsSentiment-0.30Relevance75%+24h-1.77%+72h-1.13%+7d+9.50%
- Yahoo4/23/2026, 6:41:00 PMHims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing.Sentiment-0.65Relevance60%+24h-5.38%+72h-5.38%+7d+4.98%
- Yahoo4/23/2026, 3:53:00 PMHims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?Sentiment-0.40Relevance75%+24h-5.38%+72h-5.38%+7d+4.98%
Not investment advice. See full disclaimer.